scholarly journals Pseudolumen Size and Perimeter in Prostate Cancer: Correlation with Patient Outcome

2011 ◽  
Vol 2011 ◽  
pp. 1-5
Author(s):  
Kenneth A. Iczkowski ◽  
Kathleen C. Torkko ◽  
Gregory R. Kotnis ◽  
R. Storey Wilson ◽  
Wei Huang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Patient Outcome ◽  
Multivariate Analysis ◽  
Radical Prostatectomy ◽  
Prostate Volume ◽  
Size Ratio ◽  
Size And Shape ◽  
Grade 5 ◽  
Psa Failure ◽  
Papillary Pattern

We demonstrated in 2011 that 61% of men with postoperative PSA failure had some cribriform pattern of prostate cancer, versus 16% of nonfailures ( , ). That study used digitized radical prostatectomy slides from 153 men, 76 failures (≥0.2 ng/mL) matched to 77 nonfailures. The current study's hypothesis: pseudolumen size and shape variability could stratify outcome within histologic patterns (single separate acini, separate acini with undulating lumens, fused small acini, papillary, cribriform). Pseudolumens were filled digitally on image captures from previously annotated specimens. Among all 5 patterns, pseudolumen spaces averaged smaller in failures than nonfailures. After multivariate analysis controlling for stage, age, margin, cancer amount, prostate volume, and presence of individual cells (grade 5), this retained significance only for the undulating-lumens and papillary patterns. In undulating-lumens pattern, PSA failures had smaller mean pseudolumen space sizes () but larger perimeters (), implying more pseudolumen irregularity. In papillary pattern, the number of pseudolumen spaces was higher in failures (), space size was smaller (), perimeters were smaller (), and perimeter/size ratio was higher (). In conclusion, digitally measured pseudolumen size and shape may associate with outcome.

scholarly journals Clinical and pathological variables that predict changes in tumour grade after radical prostatectomy in patients with prostate cancer

2013 ◽  
Vol 7 (1-2) ◽  
pp. 93 ◽  
Author(s):  
Stavros Sfoungaristos ◽  
Petros Perimenis
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Gleason Score ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Secondary Analysis ◽  
Intraepithelial Neoplasia ◽  
Treatment Modalities ◽  
Psa Density ◽  
Group 2

Introduction: Preoperative Gleason score is crucial, in combination with other preoperative parameters, in selecting the appropriate treatment for patients with clinically localized prostate cancer. The aim of the present study is to determine the clinical and pathological variables that can predict differences in Gleason score between biopsy and radical prostatectomy.Methods: We retrospectively analyzed the medical records of 302 patients who had a radical prostatectomy between January 2005 and September 2010. The association between grade changes and preoperative Gleason score, age, prostate volume, prostate-specific antigen (PSA), PSA density, number of biopsy cores, presence of prostatitis and high-grade prostatic intraepithelial neoplasia was analyzed. We also conducted a secondary analysis of the factors that influence upgrading in patients with preoperative Gleason score ≤6 (group 1) and downgrading in patients with Gleason score ≤7 (group 2).Results: No difference in Gleason score was noted in 44.3% of patients, while a downgrade was noted in 13.7% and upgrade in 42.1%. About 2/3 of patients with a Gleason score of ≤6 upgraded after radical prostatectomy. PSA density (p = 0.008) and prostate volume (p = 0.032) were significantly correlated with upgrade. No significant predictors were found for patients with Gleason score ≤7 who downgraded postoperatively.Conclusion: Smaller prostate volume and higher values of PSA density are predictors for upgrade in patients with biopsy Gleason score ≤6 and this should be considered when deferred treatment modalities are planned.

451: Hypomethylation of the Heparanase Promoter in Prostate Cancer and its Positive Association with Early PSA Failure after Radical Prostatectomy

2005 ◽  
Vol 173 (4S) ◽  
pp. 123-123
Author(s):  
Hiroaki Shiina ◽  
Tatsuya Ogishima ◽  
Hideki Enokida ◽  
Shinji Urakami ◽  
Toshifumi Kawakami ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Positive Association ◽  
Psa Failure

Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy.

1998 ◽  
Vol 16 (9) ◽  
pp. 3094-3100 ◽  
Author(s):  
A V D'Amico ◽  
R Whittington ◽  
S B Malkowicz ◽  
D Schultz ◽  
I Kaplan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Radical Prostatectomy ◽  
External Beam Radiation Therapy ◽  
External Beam Radiation ◽  
Clinical Staging ◽  
External Beam ◽  
Beam Radiation ◽  
Psa Failure ◽  
The Impact

PURPOSE Patients with palpable extraprostatic disease (T3) have a poor prostate-specific antigen (PSA) failure-free (bNED) survival rate after radical prostatectomy (RP) or external-beam radiation therapy (RT). This study was performed to validate or refute the prognostic value of the previously defined calculated prostate cancer volume (cV(Ca)). PATIENTS AND METHODS For patients with clinically localized disease (T1c,2), a Cox regression multivariable analysis was used to assess the ability of the cV(Ca) value to predict time to posttherapy PSA failure following RP or RT. RESULTS The cV(Ca) value was a significant predictor (P < or = .0005) of time to posttherapy PSA failure in both an RP and RT data set independent of the one used to derive the cV(Ca)-based clinical staging system. In both RP- and RT-managed patients, estimates of 3-year bNED survival were not statistically different for patients with either T1c,2 disease and a cV(Ca) greater than 4.0 cm3 (RP, 27%; RT, 18%) or T3 disease (RP, 37%; RT, 34%). Despite pathologic T2 disease, the 3-year estimate of bNED survival was at most 51% in RP-managed patients with T1c,2 disease and cV(Ca) greater than 4.0 cm3. CONCLUSION A cV(Ca) greater than 4.0 cm3 identified patients with T1c.2 disease whose bNED survival was poor after RT or RP despite pathologic T2 disease that suggests the presence of occult micrometastatic disease in many of these patients. Prospective randomized trials to evaluate the impact on survival of adjuvant systemic therapy in these high-risk patients are justified.

Utility of RhoC and ZAG protein expression as biomarkers for prediction of pSa failure following radical prostatectomy for high grade prostate cancer

Pathology ◽  
2012 ◽  
Vol 44 (6) ◽  
pp. 513-518 ◽  
Author(s):  
John Mills ◽  
Alice Oliver ◽  
Justin C. Sherwin ◽  
Mark Frydenberg ◽  
Justin S. Peters ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Protein Expression ◽  
High Grade ◽  
Psa Failure

Prostate Volume and Pathologic Prostate Cancer Outcomes After Radical Prostatectomy

Urology ◽  
2007 ◽  
Vol 70 (4) ◽  
pp. 696-701 ◽  
Author(s):  
Phillip M. Pierorazio ◽  
Michael D. Kinnaman ◽  
Matthew S. Wosnitzer ◽  
Mitchell C. Benson ◽  
James M. McKiernan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Prostate Volume ◽  
Cancer Outcomes
Sign in / Sign up

Export Citation Format

Share Document